Ex­clu­sive: Athena Coun­tou­ri­o­tis' Aven­zo nabs $150M to in-li­cense more as­sets

Athena Coun­tou­ri­o­tis and her team at Aven­zo Ther­a­peu­tics have reeled in an ad­di­tion­al $150 mil­lion just two and a half months af­ter in-li­cens­ing their first clin­i­cal-stage as­set.

With the Se­ries A-1, the biotech has now raised $347 mil­lion in to­tal fi­nanc­ing since its Au­gust 2022 in­cep­tion, Aven­zo told End­points News Tues­day morn­ing. That makes it one of the largest Se­ries A fi­nanc­ings in re­cent biotech mem­o­ry.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.